Product Name
PLOD2, siRNA
Full Product Name
PLOD2 siRNA (Mouse)
Product Synonym Names
Procollagen-lysine.2-oxoglutarate 5-dioxygenase 2; Lysyl hydroxylase 2; LH2
Product Gene Name
PLOD2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9R0B9
Specificity
PLOD2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse PLOD2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of PLOD2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
PLOD2 sirna
siRNA to inhibit PLOD2 expression using RNA interference
Applications Tested/Suitable for PLOD2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for PLOD2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001136388.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001142916.1
[Other Products]
UniProt Primary Accession #
Q9R0B9
[Other Products]
UniProt Secondary Accession #
Q8VDT4; E9QM54[Other Products]
UniProt Related Accession #
Q9R0B9[Other Products]
Molecular Weight
84,488 Da
NCBI Official Full Name
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 isoform 1
NCBI Official Synonym Full Names
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
NCBI Official Symbol
Plod2 [Similar Products]
NCBI Official Synonym Symbols
LH2; Plod-2; D530025C14Rik
[Similar Products]
NCBI Protein Information
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2
UniProt Protein Name
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2
UniProt Synonym Protein Names
Lysyl hydroxylase 2; LH2
Protein Family
Procollagen-lysine,2-oxoglutarate 5-dioxygenase
UniProt Gene Name
Plod2 [Similar Products]
UniProt Synonym Gene Names
LH2 [Similar Products]
UniProt Entry Name
PLOD2_MOUSE
UniProt Comments for PLOD2
PLOD2: Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links. Defects in PLOD2 are the cause of Bruck syndrome type 2 (BRKS2). Bruck syndrome, also known as osteogenesis imperfecta with congenital joint contractures, is an autosomal recessive disease characterized by generalized osteopenia, joint contractures at birth, fragile bones and short stature. It can be distinguished from osteogenesis imperfecta by the absence of hearing loss and dentinogenesis imperfecta, and by the presence of clubfoot and congenital joint limitations. The molecular defect is an aberrant cross-linking of bone collagen, due to underhydroxylation of lysine residues within the telopeptides of type I collagen, whereas the lysine residues in the triple helix are normal. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 1.14.11.4; Endoplasmic reticulum; Amino Acid Metabolism - lysine degradation; Oxidoreductase
Cellular Component: membrane; endoplasmic reticulum
Molecular Function: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; dioxygenase activity; L-ascorbic acid binding; metal ion binding; procollagen-lysine 5-dioxygenase activity; iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors; oxidoreductase activity
Research Articles on PLOD2
1. Authors propose that lysyl hydroxylase 2, and the subsequent increase in pyridinoline cross-links, is responsible for the persistent fibrosis in experimental osteoarthritis.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
